OncoDaily (@oncodaily) “Chemo-free just posted a big number in second-line DLBCL. @abbvie and @Genmab's” — TopicDigg
OncoDaily
@oncodaily
Where the global cancer community meets - daily news, trial breakdowns. KOL interviews, live from major cancer congresses
OncoDaily - The Voice of Oncology
加入 May 2023
8.5K 正在关注 9.4K 粉丝
Chemo-free just posted a big number in second-line DLBCL.
@abbvie and @Genmab's Phase 3 EPCORE DLBCL-4 met its primary endpoint: epcoritamab + lenalidomide reduced the risk of progression or death by 60% vs R-GemOx (HR 0.40; p<0.0001).
Strong PFS but OS and full safety are still pending. We break down what the result shows, what it doesn't yet, and why the design matters.
When the cutting edge medicine is, by design, hard to scale, are we going to build the system around the breakthrough? or the patient that can't get it?
Leave you answer in the comments below 👇
显示更多
